Abhijit Mahalingashetty, MD
Pulmonary Disease · Little River, SCNPI 1003227976
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $7,042 of the $10,284 with a category attached, or 68.5%. 30 manufacturers reported payments, led by Intuitive Surgical at 33.0% of the total. 2025 is the largest year on record at $3,591, more than ten times the $12 reported in 2020.
Across 327 payments — averaging $31.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Intuitive Surgical$3K
- AstraZeneca$893
- GSK$830
- Insmed, Inc.$678
- Boehringer Ingelheim$653
- Sanofi$543
- plus $3K from 24 others
What the payments were for
- Consulting fees$380%
- Travel & lodging$1,61416%
- Food & beverage$7,04268%
- Education$1,59015%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Intuitive Surgical | 17 | $3,394 |
| AstraZeneca | 42 | $893 |
| GSK | 55 | $830 |
| Insmed, Inc. | 23 | $678 |
| Boehringer Ingelheim | 27 | $653 |
| Sanofi | 16 | $543 |
| United Therapeutics Corporation | 13 | $524 |
| Actelion Pharmaceuticals US, Inc. | 23 | $410 |
| Regeneron Healthcare Solutions, Inc. | 11 | $289 |
| Merck | 11 | $256 |
| Baxter Healthcare | 11 | $235 |
| Mylan Specialty L.p. | 11 | $212 |
| Amgen | 8 | $199 |
| Philips North America LLC | 10 | $196 |
| Grifols USA, LLC | 8 | $173 |
| Electromed, Inc. | 13 | $171 |
| Mallinckrodt Hospital Products Inc. | 5 | $118 |
| Harmony Biosciences LLC | 3 | $73 |
| Pfizer | 4 | $71 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $71 |
| Genentech USA, Inc. | 3 | $64 |
| Verona Pharma, Inc. | 2 | $42 |
| ADMA Biomanufacturing LLC | 1 | $38 |
| Vifor Pharma, Inc. | 1 | $30 |
| Inspire Medical Systems, Inc. | 1 | $27 |
| Inogen, Inc. | 1 | $24 |
| Breas Medical, Inc. | 1 | $20 |
| Bayer | 1 | $18 |
| Vapotherm Inc | 1 | $17 |
| Viatris Specialty LLC | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Da Vinci Surgical System$3,168
- DUPIXENT$150
- AIRSUPRA$105
- BREZTRI$105
How this compares
$10,284 in reported general payments places this provider in the 75th percentile of 192 pulmonary disease providers in South Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 415 | $373,393 |
| OfevNintedanib Esylate | 24 | $330,515 |
| Prolastin CAlpha-1-Proteinase Inhibitor | 12 | $178,070 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 90 | $75,263 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 120 | $63,652 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 66 | $43,326 |
| Breo ElliptaFluticasone/Vilanterol | 66 | $37,999 |
| Ambrisentan | 13 | $32,259 |
| Spiriva RespimatTiotropium Bromide | 31 | $26,009 |
| Incruse ElliptaUmeclidinium Bromide | 20 | $9,194 |
| Bevespi AerosphereGlycopyrrolate/Formoterol Fum | 16 | $7,749 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 55 | $7,406 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 208 | $6,896 |
| SymbicortBudesonide/Formoterol Fumarate | 27 | $5,749 |
| Wixela InhubFluticasone Propion/Salmeterol | 39 | $3,556 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta, Incruse Ellipta, Arnuity Ellipta | $830 | $486,923634 claims |
| Boehringer IngelheimOfev, Stiolto Respimat, Spiriva Respimat | $653 | $399,849121 claims |
| Grifols USA, LLCProlastin C | $173 | $178,07012 claims |
| AstraZenecaBreztri Aerosphere, Bevespi Aerosphere, Symbicort | $893 | $88,761133 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 192 pulmonary disease providers in South Carolina.
Other pulmonary disease in Little River
- Kevin DineenLittle River$13K
- Abhijit RavalAnderson$2M
- Richard BoganColumbia$1.1M
- Joseph BosciaSpartanburg$701K
- Patrick FlumeCharleston$418K
- Sean CallahanGreenville$321K
- Laura HerpelColumbia$254K
- Gerard SilvestriCharleston$254K
- Arun AdlakhaRock Hill$184K
- Jake KriegmdColumbia$112K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.